Mesoblast Limited vs Nebius Group NV — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Nebius Group NV trades at $222.7 (market cap $49.06B). The key difference: Nebius Group NV is far larger — about 22.2× Mesoblast Limited's market cap, and Nebius Group NV is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | NBIS | |
|---|---|---|
Market Cap | $2.21B | $49.06B |
Sector | Technology | Technology |
52-Week High | $20.96 | $286.69 |
52-Week Low | $12.88 | $64.06 |
Enterprise Value | $2.21B | $49.26B |
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →